An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1
Abstract. Background:. Single-tablet regimen (STR) provides a convenient once-daily regimen for the prevention of human immunodeficiency virus (HIV) infection. Here, we investigated the safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a three-d...
Main Authors: | An Liu, Ruolei Xin, Hongwei Zhang, Lili Dai, Ruojun (Esther) Wu, Xi Wang, Aixin Li, Wei Hua, Jianwei Li, Ying Shao, Yue Gao, Zhangli Wang, Jiangzhu Ye, Gulimila A bu dou re xi ti, Zaicun Li, Lijun Sun, Yanjie Yin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2022-11-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002494 |
Similar Items
-
Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis
by: Abdulmajeed Alharbi
Published: (2023-05-01) -
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
by: Mao-Song Tsai, et al.
Published: (2023-01-01) -
Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023-12-01) -
Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
by: Franco Maggiolo, et al.
Published: (2022-11-01) -
A New Combined Antiretroviral Therapy In Adolescents With HIV: Bictegravir/Emtricitabine/Tenofovir Alafenamide
by: Neslihan Mete Atasever, et al.
Published: (2024-12-01)